Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adaptive Biotechnologies Corporation    ADPT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.
Sales per Business
20192020Delta
USD (in Million)%USD (in Million)%
Development Support39.5546.5%54.4455.3% +37.65%
Sequencing43.5251.2%41.4442.1% -4.78%
Regulatory Milestones2.002.4%2.502.5% +25%
Sales per region
20192020Delta
USD (in Million)%USD (in Million)%
United States85.07100%98.38100% +15.65%
Managers and Directors
NameAgeSinceTitle
Chad Robins45-Chairman & Chief Executive Officer
Julie Rubinstein482018President
Chad Cohen452015CFO, Principal Financial & Accounting Officer
Harlan Robins462009Chief Scientific Officer
Lance Baldo472019Chief Medical Officer
R. Adams522021Chief Operating & Technical Officer
Robert M. Hershberg, Dr.572013Independent Director
Peter M. Neupert642013Independent Director
Eric L. Dobmeier512016Independent Director
David Espina Goel502016Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 139,219,503 128,948,642 92.6% 0 0.0% 92.6%
Shareholders
NameEquities%
Viking Global Investors LP 29,993,708 21.9%
Matrix Capital Management Co. LP 13,115,090 9.59%
The Vanguard Group, Inc. 9,655,425 7.06%
T. Rowe Price Associates, Inc. (Investment Management) 5,954,776 4.35%
Andris A. Zoltners 3,621,016 2.65%
Massachusetts Financial Services Co. 2,895,244 2.12%
Gilder, Gagnon, Howe & Co. LLC 2,374,798 1.74%
BlackRock Fund Advisors 2,188,476 1.60%
Artisan Partners LP 2,022,619 1.48%
Neuberger Berman Investment Advisers LLC 2,009,304 1.47%
Company contact information
Adaptive Biotechnologies Corp.
1551 Eastlake Avenue East
Suite 200
Seattle, WA 98102

Phone : +1.206.659.0067
Fax : +1.206.659.0667
Web : http://www.adaptivebiotech.com
Sector Bio Diagnostics & Testing
1st jan.Capitalization (M$)
ADAPTIVE BIOTECHNOLOGIES CORPORATION-26.13%6 081
EXACT SCIENCES CORPORATION-4.47%20 464
GUARDANT HEALTH, INC.3.31%13 372
BGI GENOMICS CO., LTD.1.61%8 196
INVITAE CORPORATION-13.87%7 082
IOVANCE BIOTHERAPEUTICS, INC.-31.53%4 670
CAREDX, INC-8.42%3 438
VERACYTE, INC.-4.15%3 143
SEEGENE INC--.--%2 920
Q-LINEA AB (PUBL)-20.00%436
BIOVICA INTERNATIONAL AB (PUBL)-29.30%121
EPIGENOMICS AG-36.03%16